Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.

Wei X, Hunt G, Abdool Karim SS, Naranbhai V, Sibeko S, Abdool Karim Q, Li JF, Kashuba AD, Werner L, Passmore JA, Morris L, Heneine W, Johnson JA.

J Infect Dis. 2014 Jun 15;209(12):1916-20. doi: 10.1093/infdis/jiu026. Epub 2014 Jan 16.

2.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

3.

Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial.

Redd AD, Mullis CE, Wendel SK, Sheward D, Martens C, Bruno D, Werner L, Garrett NJ, Abdool Karim Q, Williamson C, Porcella SF, Quinn TC, Abdool Karim SS.

J Clin Microbiol. 2014 Mar;52(3):844-8. doi: 10.1128/JCM.03143-13. Epub 2013 Dec 26.

4.

No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.

Chopera DR, Mann JK, Mwimanzi P, Omarjee S, Kuang XT, Ndabambi N, Goodier S, Martin E, Naranbhai V, Karim SA, Karim QA, Brumme ZL, Ndung'u T, Williamson C, Brockman MA; CAPRISA 004 TRAPS Team.

PLoS One. 2013 Aug 28;8(8):e71758. doi: 10.1371/journal.pone.0071758. eCollection 2013.

5.

Reformulated tenofovir gel for use as a dual compartment microbicide.

Dezzutti CS, Rohan LC, Wang L, Uranker K, Shetler C, Cost M, Lynam JD, Friend D.

J Antimicrob Chemother. 2012 Sep;67(9):2139-42. doi: 10.1093/jac/dks173. Epub 2012 May 11.

6.

Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.

Matthews LT, Sibeko S, Mansoor LE, Yende-Zuma N, Bangsberg DR, Karim QA.

PLoS One. 2013;8(3):e56400. doi: 10.1371/journal.pone.0056400. Epub 2013 Mar 5.

7.

Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.

Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH; CAPRISA004 TRAPS team.

J Infect Dis. 2012 Oct 1;206(7):993-1001. Epub 2012 Jul 24.

8.

Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.

Mureithi MW, Poole D, Naranbhai V, Reddy S, Mkhwanazi NP, Sibeko S, Werner L, Abdool Karim Q, Abdool Karim S, Ndung'u T, Altfeld M; CAPRISA004 Trial Group.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):124-7. doi: 10.1097/QAI.0b013e31824f53a9.

9.

Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.

Dobard C, Sharma S, Martin A, Pau CP, Holder A, Kuklenyik Z, Lipscomb J, Hanson DL, Smith J, Novembre FJ, García-Lerma JG, Heneine W.

J Virol. 2012 Jan;86(2):718-25. doi: 10.1128/JVI.05842-11. Epub 2011 Nov 9.

10.

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.

Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S, Karim SS.

Antivir Ther. 2013;18(3):301-10. doi: 10.3851/IMP2311. Epub 2012 Aug 23.

PMID:
22914267
11.

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.

Mansoor LE, Abdool Karim Q, Mngadi KT, Dlamini S, Montague C, Nkomonde N, Mvandaba N, Baxter C, Gengiah TN, Samsunder N, Dawood H, Grobler A, Frohlich JA, Abdool Karim SS.

Trials. 2014 Dec 19;15:496. doi: 10.1186/1745-6215-15-496.

12.

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.

Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, Bumpus NN.

PLoS One. 2013;8(1):e55013. doi: 10.1371/journal.pone.0055013. Epub 2013 Jan 30.

13.

Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.

Kashuba AD, Gengiah TN, Werner L, Yang KH, White NR, Karim QA, Abdool Karim SS.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):264-9. doi: 10.1097/QAI.0000000000000607.

14.

Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.

Williams BG, Abdool Karim SS, Karim QA, Gouws E.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):207-10. doi: 10.1097/QAI.0b013e3182253c19.

15.

CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.

Valley-Omar Z, Sibeko S, Anderson J, Goodier S, Werner L, Arney L, Naranbhai V, Treurnicht F, Abrahams MR, Bandawe G, Swanstrom R, Karim QA, Karim SS, Williamson C.

J Infect Dis. 2012 Jul 1;206(1):35-40. doi: 10.1093/infdis/jis305. Epub 2012 May 2.

16.

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.

Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.

17.

Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.

Ngandu NK, Carlson JM, Chopera DR, Ndabambi N, Abdool Karim Q, Abdool Karim S, Williamson C.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):43-47. doi: 10.1097/QAI.0000000000001458.

18.

Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.

van der Straten A, Van Damme L, Haberer JE, Bangsberg DR.

AIDS. 2012 Apr 24;26(7):F13-9. doi: 10.1097/QAD.0b013e3283522272.

PMID:
22333749
19.

Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.

Celum C, Baeten JM.

Curr Opin Infect Dis. 2012 Feb;25(1):51-7. doi: 10.1097/QCO.0b013e32834ef5ef. Review.

20.

Inefficient vaginal transmission of tenofovir-resistant HIV-1.

Chateau M, Swanson MD, Garcia JV.

J Virol. 2013 Jan;87(2):1274-7. doi: 10.1128/JVI.01777-12. Epub 2012 Oct 31.

Supplemental Content

Support Center